| pubmed-article:1974517 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1974517 | lifeskim:mentions | umls-concept:C2003888 | lld:lifeskim |
| pubmed-article:1974517 | lifeskim:mentions | umls-concept:C0005823 | lld:lifeskim |
| pubmed-article:1974517 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:1974517 | lifeskim:mentions | umls-concept:C0068475 | lld:lifeskim |
| pubmed-article:1974517 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:1974517 | pubmed:dateCreated | 1990-9-18 | lld:pubmed |
| pubmed-article:1974517 | pubmed:abstractText | In this study the effect of l-nebivolol on the blood pressure lowering action of d-nebivolol was investigated after intraperitoneal administration of the drugs to spontaneously hypertensive rats. Doses of l-nebivolol which did not affect blood pressure when given alone potentiated the decrease in systolic and diastolic blood pressure induced by 1.25 mg.kg-1 d-nebivolol. The potentiating effect of l-nebivolol was seen at doses higher than 0.16 mg.kg-1. At 1.25 mg.kg-1 d-nebivolol significantly reduced the heart rate, an effect which was not potentiated by l-nebivolol in doses up to 1.25 mg.kg-1. Higher doses of l-nebivolol (2.5 and 5.0 mg.kg-1) in combination with 1.25 mg.kg-1 d-nebivolol not only lowered the blood pressure further, but also significantly reduced the heart rate; thus at these doses the enantiomers together exerted more pronounced beta 1-adrenoceptor blocking properties. This is probably disadvantageous, because d,l-nebivolol has been shown to decrease arterial blood pressure in hypertensive patients and animals before it reaches its maximal beta 1-adrenoceptor blocking effect. Therefore, the racemic mixture of 50% d-nebivolol and 50% l-nebivolol seems to contain the two compounds in near optimal proportions for an antihypertensive effect. | lld:pubmed |
| pubmed-article:1974517 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1974517 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1974517 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1974517 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1974517 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1974517 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1974517 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1974517 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1974517 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1974517 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:1974517 | pubmed:issn | 0014-2999 | lld:pubmed |
| pubmed-article:1974517 | pubmed:author | pubmed-author:JanssenP APA | lld:pubmed |
| pubmed-article:1974517 | pubmed:author | pubmed-author:RenemanR SRS | lld:pubmed |
| pubmed-article:1974517 | pubmed:author | pubmed-author:XhonneuxRR | lld:pubmed |
| pubmed-article:1974517 | pubmed:author | pubmed-author:WoutersLL | lld:pubmed |
| pubmed-article:1974517 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1974517 | pubmed:day | 8 | lld:pubmed |
| pubmed-article:1974517 | pubmed:volume | 181 | lld:pubmed |
| pubmed-article:1974517 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1974517 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1974517 | pubmed:pagination | 261-5 | lld:pubmed |
| pubmed-article:1974517 | pubmed:dateRevised | 2003-11-14 | lld:pubmed |
| pubmed-article:1974517 | pubmed:meshHeading | pubmed-meshheading:1974517-... | lld:pubmed |
| pubmed-article:1974517 | pubmed:meshHeading | pubmed-meshheading:1974517-... | lld:pubmed |
| pubmed-article:1974517 | pubmed:meshHeading | pubmed-meshheading:1974517-... | lld:pubmed |
| pubmed-article:1974517 | pubmed:meshHeading | pubmed-meshheading:1974517-... | lld:pubmed |
| pubmed-article:1974517 | pubmed:meshHeading | pubmed-meshheading:1974517-... | lld:pubmed |
| pubmed-article:1974517 | pubmed:meshHeading | pubmed-meshheading:1974517-... | lld:pubmed |
| pubmed-article:1974517 | pubmed:meshHeading | pubmed-meshheading:1974517-... | lld:pubmed |
| pubmed-article:1974517 | pubmed:meshHeading | pubmed-meshheading:1974517-... | lld:pubmed |
| pubmed-article:1974517 | pubmed:meshHeading | pubmed-meshheading:1974517-... | lld:pubmed |
| pubmed-article:1974517 | pubmed:meshHeading | pubmed-meshheading:1974517-... | lld:pubmed |
| pubmed-article:1974517 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:1974517 | pubmed:articleTitle | The l-enantiomer of nebivolol potentiates the blood pressure lowering effect of the d-enantiomer. | lld:pubmed |
| pubmed-article:1974517 | pubmed:affiliation | Cardiovascular Department, Janssen Research Foundation, Beerse Belgium. | lld:pubmed |
| pubmed-article:1974517 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1974517 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1974517 | lld:pubmed |
